보고서 요약(국문)

개요
전 세계 동물 광견병 백신 시장은 2023년 4억 6,414만 달러에 달했으며, 2024년부터 2031년까지 연평균 4.2% 성장하여 2031년에는 6억 4,698만 달러에 이를 것으로 예상됩니다.
광견병은 감염된 동물의 물림이나 타액을 통해 사람에게 전염되는 가장 치명적인 인수공통감염병 중 하나입니다. 이 감염의 가장 흔한 매개체는 개, 고양이, 박쥐, 너구리 등입니다. 광견병은 백신으로 예방 가능하므로 동물 예방접종은 광견병 박멸을 위한 필수적이고 가장 일반적으로 시행되는 조치입니다.
수의학에서 동물에 사용되는 광견병 백신은 대부분 불활성화(사멸) 백신으로, 동물의 면역 세포를 활성화하여 광견병 감염에 대한 항체를 생성하도록 합니다. 다른 유형의 광견병 백신은 ORV(경구용 광견병 백신)로, 야생 동물에게 사료에 섞어 투여하는 재조합 바이러스 벡터 기반 백신입니다.
시장 동향: 동인
광견병 퇴치를 위한 정부 정책 강화
광견병은 개를 통해 사람에게 전염되는 가장 흔한 인수공통감염병 중 하나입니다. 많은 국가에서 개 개체 수가 많아 광견병은 심각한 문제로 대두되고 있습니다. 광견병 유행 국가의 정부는 대규모 개 백신 접종을 주요 행동 계획으로 삼아 광견병 퇴치 프로그램을 적극적으로 추진하고 있습니다. 이는 비용 효율적인 전략이며 바이러스 확산을 효과적으로 차단합니다.
예를 들어, 인도 정부는 2023년 '2030년까지 개를 매개로 한 광견병 퇴치를 위한 국가 행동 계획(NAPRE)'을 발표했습니다. 이 계획은 2030년까지 인도에서 개 물림으로 인한 광견병 사망자 수를 0으로 줄이는 것을 목표로 합니다. 이 계획의 핵심 실행 계획 중 하나는 특정 지리적 지역 내 개들의 광견병 예방 접종률을 3년 연속 매년 최소 70%까지 달성하는 것입니다.
세계적으로는 세계보건기구(WHO), 세계동물보건기구(WOAH), 유엔식량농업기구(FAO), 그리고 세계광견병통제연맹(GARC)이 원헬스(One Health) 프레임워크 내에서 광견병 퇴치를 위한 연합(United Against Rabies, UAR)이라는 전략적 협력체를 구축했습니다. 이 협력체는 2030년까지 개를 매개로 한 광견병으로 인한 인명 피해를 종식시키기 위한 글로벌 전략 계획인 '2030년까지 0'을 수립하고 시행하고 있습니다.
또한 아프리카에서는 차드, 에리트레아, 케냐, 나미비아, 탄자니아, 튀니지 등 여러 국가에서 개를 매개로 한 광견병 통제 프로젝트와 계획이 활발히 시행되고 있습니다.
이러한 정부 차원의 대규모 개 예방 접종 전략은 향후 동물 광견병 백신에 대한 막대한 수요를 창출할 것으로 예상됩니다.

제약 요인
일부 저소득 국가에서는 예산 제약과 인식 부족으로 인해 예방 접종 캠페인이 효과적으로 진행되지 못할 수 있으며, 이는 해당 국가에 대한 백신 공급을 제한할 수 있습니다. 또한, 원자재 공급망의 불균형은 생산 능력에 걸림돌이 될 수 있습니다.
세분화 분석
전 세계 동물 광견병 백신 시장은 유형, 동물 유형, 투여 경로 및 지역별로 세분화됩니다.
유형 부문에서 불활화 백신은 전 세계 동물 광견병 백신 시장 점유율의 약 45.7%를 차지했습니다.
세계보건기구(WHO)에 따르면 불활화 광견병 백신은 개에 대한 주사 접종에 널리 사용 가능하며, 95% 이상의 개에서 강력한 면역 반응을 유도하는 것으로 여러 차례 입증되었습니다. 또한, 대부분의 수의 광견병 백신 제조업체는 비면역원성 및 낮은 개발 비용 때문에 이 불활화 백신 개발에 집중하고 있습니다.

예를 들어, 아래는 주요 동물 광견병 백신 제조업체 목록과 그들이 생산하는 백신 유형입니다.
위 목록은 불활화 광견병 백신의 높은 시장 점유율을 보여줍니다. 이들 제조업체는 자체적으로 백신을 공급하는 것 외에도 WHO 및 WOAH(세계동물보건기구)와 같은 기관과 협력하여 동물 예방접종 프로그램에 필요한 백신을 공급하고 있습니다.
예를 들어, 라틴 아메리카에 기반을 둔 동물 백신 제조업체이자 공급업체인 Biogénesis Bagó는 14년 동안 15개국에 1억 3,800만 도스 이상의 불활화 백신을 공급했습니다. 또한, 이 회사는 WHO와 협력하여 2030년까지 광견병을 퇴치하기 위해 노력하고 있습니다.
지역 분석
아시아 태평양 지역은 전 세계 동물 광견병 백신 시장에서 38.6%의 점유율로 시장을 주도할 것으로 예상됩니다.
아시아 태평양 지역은 인구뿐만 아니라 동물 개체 수 측면에서도 가장 인구가 많은 지역입니다. 세계동물보건기구(OIE)에 따르면 광견병 관련 사망자의 95% 이상이 아시아와 아프리카에서 발생합니다. 또한 세계보건기구(WHO)에 따르면 아시아와 아프리카는 광견병이 가장 많이 발생하는 지역입니다. 이 지역에서는 개에서 사람으로의 광견병 전염률이 높습니다. 아래 그림은 현재 광견병이 많이 발생하는 지역과 공개적으로 이용 가능한 국가 광견병 전략 계획(NSP)을 보여줍니다. 인도, 베트남, 말레이시아, 인도네시아와 같은 동남아시아 국가들은 광견병 발생률이 매우 높으며, 활발한 국가 전략 계획을 시행하고 있습니다. 마찬가지로 서태평양 지역에서는 중국이 광견병 발생률이 높고, 역시 활발한 국가 전략 계획을 시행하고 있습니다.

이러한 국가 전략 계획은 일반적으로 두 가지 핵심 실행 계획을 중심으로 수립됩니다.

1. 개에 물린 사람에게 예방 접종을 위해 광견병 백신을 제공하는 것.

2. 개에 대한 적극적인 면역을 통해 광견병 확산을 예방하는 것.

WHO의 '2030년까지 광견병 제로' 보고서에 따르면, 대규모 개 예방접종 비용은 광견병 유행 지역에서 광견병 감염 환자를 예방적으로 치료하는 비용보다 훨씬 저렴합니다. 대규모 개 예방접종에 드는 개 한 마리당 평균 비용은 4.03달러(최저 1.56달러, 최고 11.33달러)인 반면, 사람 치료 비용은 약 108달러에 달합니다.
따라서 대규모 개 예방접종은 유행 지역에서 효과적인 통제 방안입니다. 아시아 국가들은 광견병 유행이 가장 심각한 지역이며, 동물 광견병 백신 제조업체들도 많아 이 지역이 시장을 주도할 것으로 예상됩니다.

시장 세분화
유형별
• 불활화 백신
• 재조합 벡터 백신
동물 종류별
• 개
• 고양이
• 소
• 염소 및 양
• 말
• 기타
투여 경로별
• 경구
• 주사
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
동물 광견병 백신 시장의 주요 업체로는 Merck & Co., Inc., Boehringer Ingelheim International GmbH, BIO-MED, Brilliant Biopharma, Zoetis Services LLC, Indian Immunologicals Ltd., Virbac. 등이 있습니다. 엘랑코, 세바, 비오제네시스 바고 등이 포함됩니다.

보고서 구매 이유:

• 유형, 동물 종류, 투여 경로 및 지역별 글로벌 동물 광견병 백신 시장 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.
• 모든 세그먼트를 포함한 동물 광견병 백신 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 모든 주요 플레이어의 핵심 제품을 포함하는 제품 매핑 엑셀 파일을 제공합니다.

글로벌 동물 광견병 백신 시장 보고서는 약 62개의 표, 53개의 그림, 187페이지로 구성됩니다.
2024년 주요 고객
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The global animal rabies vaccine market reached US$ 464.14 million in 2023 and is expected to reach US$ 646.98 million by 2031, growing at a CAGR of 4.2% during the forecast period 2024-2031.
Rabies is one the most deadly zoonotic infections that is spread to people through infected animal bites, and saliva. The most common carriers of this infection are dogs, cats, bats, raccoons, etc. The condition is vaccine-preventible, hence immunization of animals is a necessary and most commonly followed step for eradication.
The rabies vaccine used in veterinary animals is mostly inactivated (killed) which activates the immune cells in the animal to create antibodies against the rabies infection. The other type of rabies vaccine is ORV (oral rabies vaccine) which is a recombinant viral vector-based vaccine, given to wild animals, by incorporating it in food.
Market Dynamics: Drivers
Rising government initiatives to eradicate rabies
Rabies is one of the most common zoonotic infections that spreads to humans through dogs. It has become a burden in many countries, due to the widespread dog population. The government bodies of the endemic nations have been actively taking up rabies eradication programs, with a major action plan to mass vaccinate the dogs. This is a cost-effective strategy and better eliminates the virus spread.
For instance, In 2023, the government of India unveiled the National Action Plan for Dog Mediated Rabies Elimination by 2030 (NAPRE). The initiative aims to achieve zero deaths by 2030 in India caused by dog bite-mediated rabies. One of the core action plans of this initiative is to achieve at least 70 % Anti Rabies vaccination coverage among dogs in a defined geographical area annually for 3 consecutive years.
At the global level, the World Health Organization (WHO), the World Organisation for Animal Health (WOAH), the Food and Agriculture Organization of the United Nations (FAO), and the Global Alliance for Rabies Control (GARC) have forged a strategic collaboration named United Against Rabies (UAR) in the framework of One Health. This collaboration has developed and launched a Global Strategic Plan to end human deaths from dog-mediated rabies by 2030 ‘Zero by 30’.
Additionally, in Africa, numerous dog-mediated rabies control projects and initiatives are being implemented in countries such as in Chad, Eritrea, Kenya, Namibia, Tanzania, and Tunisia.
These government initiatives, focusing on mass dog vaccination strategies are anticipated to create a huge demand for animal rabies vaccine in the forecast period.
Restraints
In some low-income countries, the vaccination drives may not effectively take place due to budget constraints and lack of awareness, limiting the supply of vaccines to these countries. Moreover, raw material supply chain discrepancies may create a hurdle to the production capacities.
Segment Analysis
The global animal rabies vaccine market is segmented based on type, animal type, route of administration, and region.
The inactivated vaccine in the type segment accounted for approximately 45.7% of the global animal rabies vaccine market share.
According to the World Health Organization (WHO) inactivated rabies vaccine is widely available for parenteral vaccination of dogs and has repeatedly been shown to result in a robust immune response in >95% of dogs. Moreover, the majority of the veterinary rabies vaccine manufacturers are focusing on developing this inactivated vaccine due to its non-immunogenic potential and low cost of development.
For instance, below is the list of top animal rabies vaccine manufacturers and the type of vaccine they are manufacturing.
The above list defines the higher market share of inactivated rabies vaccine. These manufacturers apart from independently supplying, work in collaboration with organizations such as WHO and WOAH (World Organization for Animal Health) to supply these vaccines for animal immunization programs.
For instance, Biogénesis Bagó a Latin American-based animal vaccine manufacturer and supplier, has supplied its inactivated vaccine over 14 years span to 15 countries with more than 138 million doses. Moreover, the company has been working along with WHO to eradicate rabies by 2030.
Geographical Analysis
Asia-Pacific is expected to dominate the market with a 38.6% share in the global animal rabies vaccine market.
Asia-Pacific is the most populous region, not only in terms of human population but also in animal population. According to the World Organization for Animal Health, more than 95% of rabies-related deaths occur in Asia and Africa. Moreover, according to the World Health Organization, Asia and Africa are the most endemic regions for rabies. The transmission rate of rabies from dogs to humans is higher in this region. The figures below define the current rabies endemic regions and publicly available rabies national strategic plans (NSP). South East Asian countries like India, Vietnam, Malaysia, and Indonesia are highly endemic and also have an active NSP, Likewise in the Western Pacific, China is highly endemic and also has an active NSP.
These national strategic plans usually revolve around 2 core action plans.
1. To make the rabies vaccine available to the dog-bit person for prophylaxis treatment.
2. To prevent the spread of rabies, by actively immunizing the dogs.
As per WHO’s Zero by 2030 report, the cost of mass dog immunization is far lower than prophylactic treatment of rabies-infected patients in endemic counties. The average mass dog immunization cost per dog is US$4.03 (min: US$ 1.56 - max: US$ 11.33), whereas for human treatment, this cost is nearly US$ 108.
Hence mass dog immunization is an effective control plan in the endemic regions. Asian countries being the most endemic ones combined with the availability of animal rabies vaccine manufacturers, the region is expected to dominate the market.
Market Segmentation
By Type
• Inactivated Vaccine
• Recombinant Vector Vaccine
By Animal Type
• Dogs
• Cats
• Cattle
• Goats & Sheep
• Equines
• Others
By Route of Administration
• Oral
• Parenteral
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major players in the animal rabies vaccine market include Merck & Co., Inc., Boehringer Ingelheim International GmbH, BIO-MED, Brilliant Biopharma, Zoetis Services LLC, Indian Immunologicals Ltd., Virbac., Elanco, Ceva and Biogénesis Bagóamong others.
Why Purchase the Report?
• To visualize the global animal rabies vaccine market segmentation based on type, animal type, route of administration, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of animal rabies vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global animal rabies vaccine market report would provide approximately 62 tables, 53 figures, and 187 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Animal Type
3.3. Snippet by Route of Administration
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence of rabies
4.1.1.2. Rising government initiatives to eradicate rabies
4.1.2. Restraints
4.1.2.1. High cost of vaccination programs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Inactivated Vaccine*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Recombinant Vector Vaccine
7. By Animal Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
7.1.2. Market Attractiveness Index, By Animal Type
7.2. Dogs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cats
7.4. Cattle
7.5. Goats & Sheep
7.6. Equine
7.7. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Merck & Co., Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Boehringer Ingelheim International GmbH
11.3. BIO-MED
11.4. Brilliant Biopharma
11.5. Zoetis Services LLC
11.6. Indian Immunologicals Ltd.
11.7. Virbac.
11.8. Elanco
11.9. Ceva
11.10. Biogénesis Bagó
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Merck & Co., Inc., 4.	Key Developments, Boehringer Ingelheim International GmbH, BIO-MED, Brilliant Biopharma, Zoetis Services LLC, Indian Immunologicals Ltd., Virbac., Elanco, Ceva, Biogénesis Bagó

표 목록 (Tables)

List of Tables

Table 1 Global Animal Rabies Vaccine Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Animal Rabies Vaccine Market Value, By Animal Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Animal Rabies Vaccine Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Animal Rabies Vaccine Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Animal Rabies Vaccine Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Animal Rabies Vaccine Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Animal Rabies Vaccine Market Value, By Animal Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Animal Rabies Vaccine Market Value, By Animal Type, 2022-2031 (US$ Million)

Table 9 Global Animal Rabies Vaccine Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Animal Rabies Vaccine Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 11 Global Animal Rabies Vaccine Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Animal Rabies Vaccine Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Animal Rabies Vaccine Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Animal Rabies Vaccine Market Value, By Animal Type, 2022-2031 (US$ Million)

Table 15 North America Animal Rabies Vaccine Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 16 North America Animal Rabies Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Animal Rabies Vaccine Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Animal Rabies Vaccine Market Value, By Animal Type, 2022-2031 (US$ Million)

Table 19 South America Animal Rabies Vaccine Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 20 South America Animal Rabies Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Animal Rabies Vaccine Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Animal Rabies Vaccine Market Value, By Animal Type, 2022-2031 (US$ Million)

Table 23 Europe Animal Rabies Vaccine Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 Europe Animal Rabies Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Animal Rabies Vaccine Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Animal Rabies Vaccine Market Value, By Animal Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Animal Rabies Vaccine Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Animal Rabies Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Animal Rabies Vaccine Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Animal Rabies Vaccine Market Value, By Animal Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Animal Rabies Vaccine Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Animal Rabies Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Merck & Co., Inc.: Overview

Table 34 Merck & Co., Inc.: Product Portfolio

Table 35 Merck & Co., Inc.: Key Developments

Table 36 Boehringer Ingelheim International GmbH: Overview

Table 37 Boehringer Ingelheim International GmbH: Product Portfolio

Table 38 Boehringer Ingelheim International GmbH: Key Developments

Table 39 BIO-MED: Overview

Table 40 BIO-MED: Product Portfolio

Table 41 BIO-MED: Key Developments

Table 42 Brilliant Biopharma: Overview

Table 43 Brilliant Biopharma: Product Portfolio

Table 44 Brilliant Biopharma: Key Developments

Table 45 Zoetis Services LLC: Overview

Table 46 Zoetis Services LLC: Product Portfolio

Table 47 Zoetis Services LLC: Key Developments

Table 48 Indian Immunologicals Ltd.: Overview

Table 49 Indian Immunologicals Ltd.: Product Portfolio

Table 50 Indian Immunologicals Ltd.: Key Developments

Table 51 Virbac.: Overview

Table 52 Virbac.: Product Portfolio

Table 53 Virbac.: Key Developments

Table 54 Elanco: Overview

Table 55 Elanco: Product Portfolio

Table 56 Elanco: Key Developments

Table 57 Ceva: Overview

Table 58 Ceva: Product Portfolio

Table 59 Ceva: Key Developments

Table 60 Biogénesis Bagó: Overview

Table 61 Biogénesis Bagó: Product Portfolio

Table 62 Biogénesis Bagó: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 2 Global Animal Rabies Vaccine Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Animal Rabies Vaccine Market Share, By Animal Type, 2023 & 2031 (%)

Figure 4 Global Animal Rabies Vaccine Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 5 Global Animal Rabies Vaccine Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Animal Rabies Vaccine Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Inactivated Vaccine Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 8 Recombinant Vector Vaccine Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 9 Global Animal Rabies Vaccine Market Y-o-Y Growth, By Animal Type, 2023-2031 (%)

Figure 10 Dogs Animal Type in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 11 Cats Animal Type in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 12 Cattle Animal Type in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 13 Goats & Sheep Animal Type in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 14 Equines Animal Type in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 15 Others Animal Type in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 16 Global Animal Rabies Vaccine Market Y-o-Y Growth, By Route of Administration, 2023-2031 (%)

Figure 17 Oral Route of Administration in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 18 Parenteral Route of Administration in Global Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 19 Global Animal Rabies Vaccine Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 20 North America Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 21 North America Animal Rabies Vaccine Market Share, By Type, 2023 & 2031 (%)

Figure 22 North America Animal Rabies Vaccine Market Share, By Animal Type, 2023 & 2031 (%)

Figure 23 North America Animal Rabies Vaccine Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 24 North America Animal Rabies Vaccine Market Share, By Country, 2023 & 2031 (%)

Figure 25 South America Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 26 South America Animal Rabies Vaccine Market Share, By Type, 2023 & 2031 (%)

Figure 27 South America Animal Rabies Vaccine Market Share, By Animal Type, 2023 & 2031 (%)

Figure 28 South America Animal Rabies Vaccine Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 29 South America Animal Rabies Vaccine Market Share, By Country, 2023 & 2031 (%)

Figure 30 Europe Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 31 Europe Animal Rabies Vaccine Market Share, By Type, 2023 & 2031 (%)

Figure 32 Europe Animal Rabies Vaccine Market Share, By Animal Type, 2023 & 2031 (%)

Figure 33 Europe Animal Rabies Vaccine Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 34 Europe Animal Rabies Vaccine Market Share, By Country, 2023 & 2031 (%)

Figure 35 Asia-Pacific Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 36 Asia-Pacific Animal Rabies Vaccine Market Share, By Type, 2023 & 2031 (%)

Figure 37 Asia-Pacific Animal Rabies Vaccine Market Share, By Animal Type, 2023 & 2031 (%)

Figure 38 Asia-Pacific Animal Rabies Vaccine Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 39 Asia-Pacific Animal Rabies Vaccine Market Share, By Country, 2023 & 2031 (%)

Figure 40 Middle East and Africa Animal Rabies Vaccine Market Value, 2022-2031 (US$ Million)

Figure 41 Middle East and Africa Animal Rabies Vaccine Market Share, By Type, 2023 & 2031 (%)

Figure 42 Middle East and Africa Animal Rabies Vaccine Market Share, By Animal Type, 2023 & 2031 (%)

Figure 43 Middle East and Africa Animal Rabies Vaccine Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 44 Merck & Co., Inc.: Financials

Figure 45 Boehringer Ingelheim International GmbH: Financials

Figure 46 BIO-MED: Financials

Figure 47 Brilliant Biopharma: Financials

Figure 48 Zoetis Services LLC: Financials

Figure 49 Indian Immunologicals Ltd.: Financials

Figure 50 Virbac.: Financials

Figure 51 Elanco: Financials

Figure 52 Ceva: Financials

Figure 53 Biogénesis Bagó: Financials

세계 동물 광견병 백신 시장 – 2024-2031년

Global Animal Rabies Vaccine Market - 2024-2031